These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12712217)

  • 21. [Gastroesophageal reflux disease and dyspepsia--drug therapy].
    Gräter H
    Praxis (Bern 1994); 2006 Aug; 95(31-32):1179-83. PubMed ID: 16909686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extraesophageal and atypical manifestations of GERD.
    Wong WM; Fass R
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S33-43. PubMed ID: 15324380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
    Haag S; Holtmann G
    Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
    Gillessen A
    MMW Fortschr Med; 2010 Apr; 152 Suppl 1():21-9. PubMed ID: 20942304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton pump inhibition. An effective, safe approach to GERD management.
    Berardi RR
    Postgrad Med; 2001 Oct; Spec No():24-35. PubMed ID: 11868428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
    Kahrilas PJ; Howden CW; Hughes N
    Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency and clinical implications of supraesophageal and dyspeptic symptoms in gastroesophageal reflux disease.
    Mearin F; Ponce J; Ponce M; Balboa A; Gónzalez MA; Zapardiel J
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):665-74. PubMed ID: 22330237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors for GERD in children.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):17-8. PubMed ID: 17325623
    [No Abstract]   [Full Text] [Related]  

  • 31. Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
    Johnson DA; Katz PO
    Rev Gastroenterol Disord; 2008; 8(2):98-108. PubMed ID: 18641592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hold it! Are you taking your reflux meds correctly? PPIs for heartburn and GERD are effective--but only when used according to directions.
    Johns Hopkins Med Lett Health After 50; 2014 Oct; 26(10):3. PubMed ID: 25306565
    [No Abstract]   [Full Text] [Related]  

  • 33. The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--clinical overview of gastroesophageal reflux disease. Roundtable discussion.
    Danzig J; Navarro R; Inami D; Morreale A; Tokayer A; Wong W; Compton J; Page RN; Sweet FB
    Manag Care Interface; 2001; Suppl B():13-20; discussion 24-7, 31-3. PubMed ID: 11569294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD.
    Holtmann G; Bigard MA; Malfertheiner P; Pounder R
    Int J Clin Pharm; 2011 Jun; 33(3):493-500. PubMed ID: 21472476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PPI use in the OTC era: who to treat, with what, and for how long?
    Inadomi JM; Fendrick AM
    Clin Gastroenterol Hepatol; 2005 Mar; 3(3):208-15. PubMed ID: 15765438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical therapy of extraesophageal gastroesophageal reflux disease.
    Katz PO
    J Clin Gastroenterol; 2000 Apr; 30(3 Suppl):S42-4. PubMed ID: 10777172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM; McIntyre L; Bernard L; Fendrick AM
    Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of reflux disease management and the role of Nexium. Proceedings of a symposium. Porto, Portugal, 7 October 2000.
    Eur J Gastroenterol Hepatol; 2001 Sep; 13 Suppl 3():S1-95. PubMed ID: 11831194
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.